Adrenoleukodystrophy Market By Disease Type (Childhood Cerebral Adrenoleukodystrophy, Adrenomyeloneuropathy, Adrenal Insufficiency, Adult Cerebral Adrenoleukodystrophy, Other Forms), By Treatment (Hematopoietic Stem Cell Transplantation, Gene Therapy, Adrenal Hormone Replacement, Symptomatic and Supportive Care, Emerging Oral Therapies), By Diagnostic Service (Newborn Screening, VLCFA Testing, ABCD1 Genetic Testing, Brain MRI, Adrenal Function Testing, HLA and Donor Matching), By End User (Hospitals and Transplant Centers, Leukodystrophy and Neurology Clinics, Genetic Testing Laboratories, Endocrinology Clinics, Academic and Clinical Research Institutions), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Adrenoleukodystrophy Market: Newborn Screening, Early Treatment, and the AMN Pipeline Reshape Rare-Disease Care

The Global Adrenoleukodystrophy Market was valued at USD 80 million in 2025 and is projected to reach USD 650 million by 2032, expanding at a CAGR of 34.9% during 2026–2032, according to internal projections by Strategic Market Research. The forecast represents an absolute revenue increase of USD 570 million and an 8.1-fold expansion over seven years.

 

Adrenoleukodystrophy, or ALD, is a rare inherited disorder that mainly affects the nervous system and adrenal glands. It is caused by changes in the ABCD1 gene on the X chromosome, which prevent the body from properly breaking down very-long-chain fatty acids. Their buildup damages the protective covering around nerves and can also impair adrenal function.

 

Childhood cerebral ALD represents approximately 30%–35% of affected males, AMN accounts for around 40%–45% of male presentations, adolescent cerebral disease represents about 5%, and adult cerebral disease accounts for approximately 20%. Primary adrenal insufficiency without apparent neurological involvement initially occurs in about 10% of affected males. These patient shares shape demand across cerebral treatment, adult neurological care, and lifelong endocrine management.

 

Disease Burden Extends Beyond Childhood Cerebral ALD

Childhood cerebral ALD creates the most urgent treatment demand because brain damage can progress quickly once active lesions appear. Adrenomyeloneuropathy, or AMN, creates a longer-duration care burden involving progressive walking difficulty, leg weakness, stiffness, pain, and bladder or bowel problems.

AMN affects approximately 40%–45% of males as a presenting neurological form. Around 70% of men with AMN already have impaired adrenal function when neurological symptoms appear, increasing the need for combined neurological and endocrine management. Brain involvement may eventually develop in 20%–63% of people with AMN, creating additional demand for MRI surveillance and specialist assessment.

The female patient population is also commercially relevant. An AMN-like condition develops in an estimated 65%–80% of women carrying an ABCD1 variant as they age, although progression is generally slower than in males. Women therefore represent a substantial long-term neurological-care segment despite their low risk of childhood cerebral disease or adrenal failure.

Adrenal insufficiency creates recurring treatment demand across several disease forms. Adrenal function is abnormal in approximately 90% of neurologically symptomatic boys and 70% of men with AMN. Hormone replacement is far less expensive than transplantation or gene therapy, but its revenue contribution is supported by lifelong treatment, endocrinology visits, regular blood tests, and emergency-care planning.

 

Newborn Screening Expands the Diagnosed Population

The addition of X-linked ALD to the U.S. Recommended Uniform Screening Panel shifted diagnosis from symptom-based identification toward detection during infancy. Newborn screening can identify abnormal disease-related markers before neurological damage becomes visible, after which positive results are followed by confirmatory blood testing and ABCD1 analysis.

Screening cannot predict which form of ALD a child will develop. Every confirmed male infant therefore requires long-term adrenal and neurological follow-up. Around 30%–35% of affected boys develop childhood cerebral ALD, while other patients may first develop adrenal insufficiency or AMN later in life.

The screening pathway supports demand across public-health laboratories, genetic-testing providers, imaging centers, pediatric endocrinologists, leukodystrophy clinics, transplant hospitals, and family-counselling services. It also identifies affected relatives through family testing. A woman carrying an ABCD1 variant has a 50% probability of passing it to each child, while affected fathers transmit the variant to all daughters and no sons.

Regional screening expansion has the greatest market effect when patients can access regular MRI examinations and specialist care. Screening raises the diagnosed population, while treatment revenue depends on whether active cerebral disease is identified early enough for transplantation or gene therapy.

 

Early Diagnosis Controls Treatment Eligibility

Cerebral ALD has a narrow treatment window. Patients generally achieve better outcomes when brain involvement remains limited and neurological symptoms are absent or mild. Once major cognitive, visual, communication, or movement problems develop, transplantation and gene therapy are less likely to preserve function.

The difference between early and advanced treatment creates a measurable commercial divide. A study involving 59 cerebral-ALD patients found that four-year survival without major disability or a second transplant reached 66% among patients treated at an early stage, compared with 41% among patients with advanced disease. Treatment-related mortality was 7% in the early-stage group and 22% in the advanced group.

These results make repeated MRI monitoring one of the most commercially important diagnostic services in the market. Imaging capacity, specialist interpretation, donor searches, payer authorization, and hospital availability directly affect how many diagnosed patients progress to high-value treatment.

 

Stem Cell Transplantation Retains a Central Position

Donor stem cell transplantation remains an established disease-modifying option for early cerebral ALD. Its success depends on the stage of brain involvement, the quality of the donor match, and the patient’s neurological condition before treatment.

Matched sibling and well-matched unrelated donors generally provide the most favorable route. Mismatched donors can increase the risk of graft failure, infection, transplant-related death, and graft-versus-host disease.

The transplantation segment includes donor registries, compatibility testing, stem cell collection, preparation medicines, inpatient treatment, infection prevention, and long-term follow-up. These supporting services distribute revenue beyond the transplant procedure itself.

Transplantation cannot reverse advanced neurological damage and is not routinely used without active cerebral disease. It also does not reliably prevent the later spinal-cord problems associated with AMN, leaving a much larger adult patient segment dependent on supportive care and emerging drug development.

 

Skysona Remains the Only Approved Gene Therapy

Skysona, or elivaldogene autotemcel, remains the only FDA-approved gene therapy specifically for early, active cerebral ALD. Following a 2025 labeling change, its use is limited to boys aged 4–17 years who do not have an available HLA-matched donor for stem cell transplantation.

The therapy uses the patient’s own blood stem cells, which are modified to carry working copies of the ABCD1 gene and returned to the body. Its commercial pathway includes stem cell collection, individualized manufacturing, treatment preparation, hospitalization, infusion, and prolonged monitoring.

Long-term research involving 32 boys found 94% overall survival at 24 months and 91% survival without major functional disability. At approximately six years of median follow-up, neurological function remained stable in 30 of the 32 participants, or 94%, while 81% remained free from major functional disabilities.

Safety concerns now have a major effect on adoption. By August 2025, the FDA had identified blood cancers in 10 of 67 clinical-trial participants, representing 15% of the treated trial population. The FDA strengthened the boxed warning, restricted eligibility, and required lifelong blood-cancer monitoring.

Skysona had a wholesale acquisition cost of USD 3 million and was supplied through six active U.S. treatment centers as of March 2025. The limited center network and strict eligibility requirements produce a high-value but low-volume commercial model.

Skysona generated USD 9.9 million in net product revenue during 2024, down 19.8% from USD 12.4 million in 2023. Its share of bluebird bio’s total product revenue decreased from 42.6% in 2023 to 11.8% in 2024, a decline of 30.7 percentage points, as the company’s broader gene-therapy portfolio expanded. Total company product revenue increased by 188.3%, from USD 29.1 million to USD 83.8 million, during the same period.

The decline in Skysona revenue reflects the uneven timing of one-time infusions in a market with only a few eligible annual patients rather than a conventional recurring-prescription model. Bluebird bio was subsequently acquired and renamed Genetix Biotherapeutics, which now manages the therapy’s manufacturing, payer coordination, center support, and safety-monitoring requirements.

 

Leriglitazone Remains the Most Advanced Drug Candidate

Leriglitazone, developed by Minoryx Therapeutics, is the most advanced pharmacological candidate in the market. Minoryx has completed late-stage development, and its European application for pediatric and adult male patients with cerebral ALD remains under EMA review. A U.S. registration study is also recruiting adult men with progressive cerebral disease.

The 96-week NEXUS study enrolled 23 boys aged 2–12 years with early cerebral lesions. Twenty patients were included in the main analysis, and seven, or 35%, met the study’s disease-arrest criteria, compared with a predefined natural self-arrest benchmark of 10%. The 25-percentage-point difference supports leriglitazone’s positioning as the nearest potential pharmacological market entrant.

Leriglitazone was also evaluated in adults with AMN. The ADVANCE trial did not achieve its main walking-distance endpoint, although six placebo recipients developed cerebral disease compared with none receiving leriglitazone. This has positioned the candidate more strongly in cerebral ALD than in the wider chronic AMN population.

An approval would introduce an oral alternative for patients who cannot receive transplantation or gene therapy. It could also shift a portion of market revenue from one-time hospital procedures toward longer-duration pharmaceutical treatment.

 

VK0214 Has Completed Early Clinical Testing

Viking Therapeutics’ VK0214 is an oral candidate being developed primarily for adult AMN. The Phase Ib study included six placebo recipients, eight patients receiving a lower dose, and nine receiving a higher dose over 28 days.

Average levels of one major VLCFA marker increased by 20.8% in the placebo group but declined by 17.4% and 17.6% in the two VK0214 groups. Another disease-related marker declined by 8.4% at the lower dose and 14.8% at the higher dose, compared with a 23.1% increase in the placebo group.

The results demonstrate activity against disease-related blood markers, but a larger trial must establish whether treatment preserves walking ability or slows disability. VK0214 therefore remains behind leriglitazone in development and currently contributes pipeline value rather than commercial revenue.

 

PXL065 and PXL770 Have Not Advanced into ALD Trials

Poxel proposed separate 12-week Phase IIa studies of PXL065 and PXL770 in adult men with AMN. Both candidates received FDA Fast Track and Orphan Drug designations in 2022, but the proposed studies remained dependent on financing.

PXL770 was sold in March 2026 for development in another disease area, while PXL065 has also been repositioned toward other conditions. The active ALD pipeline is therefore narrower than the number of previously announced candidates suggests, with leriglitazone and VK0214 accounting for most of the current pharmaceutical-development opportunity.

 

AMN Represents the Largest Untreated Opportunity

No disease-modifying medicine is approved for chronic AMN. Current care relies on physical therapy, mobility support, pain management, bladder and bowel care, and medicines used to reduce muscle stiffness.

AMN represents approximately 40%–45% of male disease presentations, while AMN-like neurological symptoms affect an estimated 65%–80% of women carrying an ABCD1 variant later in life. This creates a larger potential long-term drug-treatment population than the narrow group eligible for cerebral-ALD gene therapy.

A treatment capable of slowing AMN progression would expand market revenue from pediatric transplant centers into adult neurology, rehabilitation, and long-term rare-disease care. It would also introduce recurring pharmaceutical revenue into a market currently dominated by monitoring, supportive care, transplantation, and a small number of one-time gene-therapy procedures.

 

Market Outlook

The adrenoleukodystrophy market is projected to expand from USD 80 million in 2025 to USD 650 million by 2032, adding USD 570 million in annual revenue at a CAGR of 34.9%. The 8.1-fold projected expansion reflects the small starting revenue base, broader screening, high-value gene therapy, and the potential entry of oral treatments.

Skysona has established the commercial gene-therapy segment, but its 15% reported blood-cancer rate among clinical-trial participants, strict eligibility requirements, and low annual treatment volume restrict adoption. Its USD 9.9 million net revenue and 11.8% share of bluebird’s 2024 product portfolio show that even a USD 3 million therapy can generate uneven revenue when the eligible population is extremely small.

Leriglitazone is the nearest potential oral competitor and could broaden treatment beyond children eligible for transplant-based intervention. VK0214 targets the larger untreated AMN population, while the termination or repositioning of other programs shows the financial barriers facing the pipeline.

The strongest long-term revenue opportunity lies in a treatment that can delay AMN disability or control cerebral ALD without donor dependence, personalized cell manufacturing, or intensive transplant preparation. Such a product could shift the market from a small procedure-led segment toward broader, recurring pharmaceutical treatment while supporting the projected 34.9% CAGR through 2032.

 

Adrenoleukodystrophy Market Report Coverage Table

 

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 80 Million
Revenue Forecast in 2032	USD 650 Million
Overall Growth Rate	CAGR of 34.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Disease Type, By Treatment, By Diagnostic Service, By End User, By Geography
By Disease Type	Childhood Cerebral Adrenoleukodystrophy, Adrenomyeloneuropathy (AMN), Adrenal Insufficiency, Adult Cerebral Adrenoleukodystrophy, Other Forms
By Treatment	Hematopoietic Stem Cell Transplantation, Gene Therapy, Adrenal Hormone Replacement, Symptomatic and Supportive Care, Emerging Oral Therapies
By Diagnostic Service	Newborn Screening, Very-Long-Chain Fatty Acid (VLCFA) Testing, ABCD1 Genetic Testing, Brain MRI, Adrenal Function Testing, HLA and Donor Matching
By End User	Hospitals and Transplant Centers, Leukodystrophy and Neurology Clinics, Genetic Testing Laboratories, Endocrinology Clinics, Academic and Clinical Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Expansion of newborn screening programs, increasing early diagnosis of cerebral ALD, rising demand for gene therapy and stem cell transplantation, growing AMN treatment pipeline, and increasing investment in rare-disease therapeutics
Customization Option	Available upon request